US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Explore Our Free-Market Analysis Sample – Instant Access: – https://www.astuteanalytica.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market ...

In a powerful act of compassion and community, Starr’s Mill High School organized an early graduation for rising senior ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

A coalition of ALS patients and caregivers is petitioning the FDA to review available data on the stem cell therapy NurOwn ...

Brain-machine interfaces (BMIs) are becoming lifelines for people facing severe motor impairments. For many individuals with ...

As a result of being afflicted with PLS, he is unable to walk and is dependent on a caregiver for help with his daily needs.

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

Neurizon Therapeutics has announced it has received positive feedback from the US Food and Drug Administration (FDA) on its ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Documenting his experiences has proven to be the outlet Darin Nakakihara needs in the wake of his ALS diagnosis.